LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific (EUFI.PA), the global scientific leader in bioanalytical testing and a leader in clinical diagnostics testing, announces a share purchase agreement with Transgenic Inc. (2342:JP, Tokyo stock exchange) to acquire Genetic Lab Co.,Ltd. (�G Lab�), a molecular biology based testing provider for diagnostics, biomarker development and drug discovery. The acquisition will further enhance Eurofins� expansion in Asia and complement its global network of clinical diagnostics laboratories focused on specialised and advanced genetic testing.

G Lab employs over 70 staff and generated revenues of over EUR 13m in the financial year ending March 2021. Initially established as a genetics technology based bio venture in 2000, G Lab has developed a reputation among clinical communities in Japan for the CAP accredited quality services provided by its technical experts, in-house medical pathologists and cytotechnologists. G Lab also provides diversified testing services supporting biomarker development for companion drugs. Since Mar 2020, G Lab has played an important role in the COVID-19 response in Japan, by facilitating PCR testing, and supporting Hokkaido prefecture and Sapporo city with their COVID-19 testing programmes

Through this acquisition, the Eurofins network will further strengthen its position in the Japanese market, where it is currently the market leader in environment testing and non-invasive prenatal testing, by extending its service offering in BioPharma services and clinical testing in Japan, notably increasing its COVID-19 testing product and service offering to support the fight against the pandemic.

Notes to Editors:

For more information, please visit www.eurofins.com.

About Eurofins � the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins� companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Investor Relations

Eurofins Scientific SE

Yuya Kusunoki

+32 2 766 1620

[email protected]